The field of immunotherapy in cHL has recently incorporated the use of newer PD-1 inhibitors, as well as anti-CTLA-4 monoclonal antibodies and anti-LAG3 (respectively ipilimumab and favezelimab), in combination with pembrolizumab or nivolumab [10,11,12,13,14,15,16,17,18]. This evidence concerns the gene LAG3 and classic Hodgkin lymphoma.